Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes plc 2026 Q3 - Results - Earnings Call Presentation
Alkermes (ALKS) Stock Could Be Overvalued Following ALKS 7290 Trial Launch
RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68
HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50
Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
Alkermes (ALKS) Q3 2026 Earnings Call Transcript
Alkermes to Present at Upcoming Investor Conferences
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript
What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes plc Q3 2026 Earnings Call Summary
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes: Q3 Earnings Snapshot
Alkermes plc Reports Third Quarter 2026 Financial Results
Alkermes Q3 2026 Earnings Call Transcript
Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate
Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.